Cognitive ImpairmentNCT07742605
A Clinical Trial to Evaluate the Effects of a Supplement on Cognitive Performance
A study testing Xula Herbs Mind Food Supplement in people with Cognitive Impairment and Brain Fog, run by Xula Wellness LLC at 1 site in United States.
Trial summary
This study evaluates the effects of the Xula Herbs Mind Food supplement on cognitive performance in adults aged 25-70 who report difficulty concentrating, memory challenges, brain fog, and low productivity. The trial is a single-arm, open-label, virtual study conducted over 6 weeks in 35 participants. Read more about this study
- Who is it for?
- Ages 25 to 70 years
- Conditions the study is for
- Cognitive Impairment, Brain Fog, Memory Difficulties
- What is being tested?
- Xula Herbs Mind Food Supplement
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 35 participants
- Where
- 1 siteUnited States
- Study dates
- 11 Jul 2025to 30 Sep 2025
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 25 to 70 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Be male or female.
- Be aged 25-70.
- Anyone experiencing issues with all of the following over the past four weeks: difficulty concentrating or low mental sharpness
- difficulty with memory
- experiences of brain fog or lack of mental clarity
- feeling of low productivity.
Show all 9Show fewer
- Willing to refrain from taking any new products, over-the-counter medications, or supplements that may affect cognitive ability during the test period.
- If taking any products, over-the-counter medications, or supplements that may affect cognitive ability, has been doing so consistently for at least three months and is willing to maintain this routine for the duration of the study.
- Anyone who is generally healthy - does not live with any uncontrolled chronic disease.
Who cannot join
- Anyone with pre-existing chronic conditions that would prevent participants from adhering to the protocol, including oncological and psychiatric disorders.
- Anyone with any allergies or sensitivities to any of the study product ingredients.
- Anyone who is pregnant, breastfeeding, or trying to conceive (or who will be at any point during the study period).
- Anyone unwilling to follow the study protocol.
- Anyone diagnosed with a neurodegenerative condition.
- Anyone taking an anticoagulant (also commonly referred to as a blood thinner) prescription medication.
Show all 11Show fewer
- Anyone with liver disease or kidney disease.
- Anyone taking hormonal birth control or contraceptives.
- Anyone with a history of substance abuse.
- Anyone who drinks heavily (8 or more alcoholic drinks per week for women or 15 or more alcoholic drinks per week for men).
- Currently partaking in another research study or will be partaking in any other research study at any point during this study's duration.
Trial locations and contacts
1 site in 1 country.
About this study
This study evaluates the effects of the Xula Herbs Mind Food supplement on cognitive performance in adults aged 25-70 who report difficulty concentrating, memory challenges, brain fog, and low productivity. The trial is a single-arm, open-label, virtual study conducted over 6 weeks in 35 participants.
Participants will use the test product three times daily (sprayed three times under the tongue, at least 30 minutes before a meal, and not after 6 pm) for the duration of the study. Cognitive performance will be assessed via a Cognitive Battery Test at Baseline and Week 6, and self-reported questionnaires will be completed at Baseline, Week 2, Week 4, and Week 6.
- Conditions
- Cognitive Impairment, Brain Fog, Memory Difficulties, Difficulty Concentrating, Mental Clarity, Cognitive Performance
- Being tested
- Xula Herbs Mind Food Supplement
- Medical subject headings
- Cognitive Dysfunction, Mental Fatigue
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Xula Herbs Mind Food SupplementDietary supplement
All 35 participants receive the Xula Herbs Mind Food supplement taken three times daily by spraying three times under the tongue, at least 30 minutes before a meal and not after 6 pm, for 6 weeks
| Study group | Role | What they receive |
|---|---|---|
| Xula Herbs Mind Food Supplement | Experimental | Not described Receives: Dietary Supplement: Xula Herbs Mind Food Supplement |
What is being measured
The primary outcome is the main question the study is designed to answer.
Change in Cognitive Battery Test Score (Polygons)
Change in performance on the Polygons timed processing test, measuring the brain's ability to sort and clarify information and judge the correct response, assessed via the Cognitive Battery Test
Measured: Baseline and Week 6
Change in Cognitive Battery Test Score (Double Trouble)
Change in performance on the Double Trouble timed test, measuring selective attention and processing speed based on the Stroop paradigm, assessed via the Cognitive Battery Test
Measured: Baseline and Week 6
Change in Cognitive Battery Test Score (Feature Match)
Change in performance on the Feature Match timed focus and processing task, assessed via the Cognitive Battery Test
Measured: Baseline and Week 6
Change in Cognitive Battery Test Score (Paired Associates)
Change in performance on the Paired Associates memory task, measuring recall of sequences and locations of items in increasing quantity, assessed via the Cognitive Battery Test
Measured: Baseline and Week 6
Change in Cognitive Battery Test Score (Digit Span)
Change in performance on the Digit Span task, measuring short-term memory and attention by recalling displayed number sequences of increasing length, assessed via the Cognitive Battery Test
Measured: Baseline and Week 6
Change in Cognitive Battery Test Score (Spatial Planning)
Change in performance on the Spatial Planning timed task, measuring executive function and ability to reorganize numbers into correct order, assessed via the Cognitive Battery Test
Measured: Baseline and Week 6
Secondary outcomes (6)
Change in Self-Reported Mental Clarity
Change in participant-reported experiences of mental clarity assessed via self-report questionnaire
Measured: Baseline, Week 2, Week 4, and Week 6
Change in Self-Reported Focus
Change in participant-reported ability to focus and concentrate assessed via self-report questionnaire
Measured: Baseline, Week 2, Week 4, and Week 6
Change in Self-Reported Memory Function
Change in participant-reported memory function assessed via self-report questionnaire
Measured: Baseline, Week 2, Week 4, and Week 6
Change in Self-Reported Alertness
Change in participant-reported alertness assessed via self-report questionnaire
Measured: Baseline, Week 2, Week 4, and Week 6
Change in Self-Reported Mood
Change in participant-reported mood assessed via self-report questionnaire
Measured: Baseline, Week 2, Week 4, and Week 6
Change in Self-Reported Brain Fog
Change in participant-reported experiences of brain fog assessed via self-report questionnaire
Measured: Baseline, Week 2, Week 4, and Week 6
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted3 Aug 2026
- Study start11 Jul 2025
- Primary completion30 Sep 2025
- Study completion30 Sep 2025
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Cognitive ImpairmentStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 35 participants (actual)
Sponsor and investigators
- Lead sponsor
- Xula Wellness LLC
- Sponsor type
- Industry (pharma, biotech, devices)
- Collaborators
- Citruslabs
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07742605
- Sponsor's protocol ID
- 20789
- Other IDs
- legacy-20789
- Status last verified
- Jul 2026
- First submitted
- 28 Jul 2026
- Last updated
- 3 Aug 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 3 Aug 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Clinical Trial to Evaluate the Effects of a Supplement on Cognitive Performance
- ClinicalTrials.gov ID
- NCT07742605
- Acronym / sponsor ID
- 20789
- Conditions
- Cognitive Impairment, Brain Fog, Memory Difficulties, Difficulty Concentrating, Mental Clarity, Cognitive Performance
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 35 participants (actual)
- Lead sponsor
- Xula Wellness LLCIndustry (pharma, biotech, devices)
- Collaborators
- Citruslabs
- Study start
- 11 Jul 2025 (actual)
- Primary completion
- 30 Sep 2025 (actual)
- Study completion
- 30 Sep 2025 (actual)
- First posted
- 3 Aug 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This study evaluates the effects of the Xula Herbs Mind Food supplement on cognitive performance in adults aged 25-70 who report difficulty concentrating, memory challenges, brain fog, and low productivity. The trial is a single-arm, open-label, virtual study conducted over 6 weeks in 35 participants.
Participants will use the test product three times daily (sprayed three times under the tongue, at least 30 minutes before a meal, and not after 6 pm) for the duration of the study. Cognitive performance will be assessed via a Cognitive Battery Test at Baseline and Week 6, and self-reported questionnaires will be completed at Baseline, Week 2, Week 4, and Week 6.
Study design
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Xula Herbs Mind Food Supplement | Experimental | Dietary Supplement: Xula Herbs Mind Food Supplement |
Who may qualify
- Ages
- 25 to 70 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (9 listed)
- Be male or female.
- Be aged 25-70.
- Anyone experiencing issues with all of the following over the past four weeks: difficulty concentrating or low mental sharpness
- difficulty with memory
- experiences of brain fog or lack of mental clarity
Key exclusion criteria (11 listed)
- Anyone with pre-existing chronic conditions that would prevent participants from adhering to the protocol, including oncological and psychiatric disorders.
- Anyone with any allergies or sensitivities to any of the study product ingredients.
- Anyone who is pregnant, breastfeeding, or trying to conceive (or who will be at any point during the study period).
- Anyone unwilling to follow the study protocol.
- Anyone diagnosed with a neurodegenerative condition.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Xula Herbs Mind Food SupplementAll 35 participants receive the Xula Herbs Mind Food supplement taken three times daily by spraying three times under the tongue, at least 30 minutes before a meal and not after 6 pm, for 6 weeks | Dietary supplement | Xula Herbs Mind Food Supplement |
Primary outcome
Change in Cognitive Battery Test Score (Polygons)
Time frame: Baseline and Week 6
Change in performance on the Polygons timed processing test, measuring the brain's ability to sort and clarify information and judge the correct response, assessed via the Cognitive Battery Test
Change in Cognitive Battery Test Score (Double Trouble)
Time frame: Baseline and Week 6
Change in performance on the Double Trouble timed test, measuring selective attention and processing speed based on the Stroop paradigm, assessed via the Cognitive Battery Test
Change in Cognitive Battery Test Score (Feature Match)
Time frame: Baseline and Week 6
Change in performance on the Feature Match timed focus and processing task, assessed via the Cognitive Battery Test
Change in Cognitive Battery Test Score (Paired Associates)
Time frame: Baseline and Week 6
Change in performance on the Paired Associates memory task, measuring recall of sequences and locations of items in increasing quantity, assessed via the Cognitive Battery Test
Change in Cognitive Battery Test Score (Digit Span)
Time frame: Baseline and Week 6
Change in performance on the Digit Span task, measuring short-term memory and attention by recalling displayed number sequences of increasing length, assessed via the Cognitive Battery Test
Change in Cognitive Battery Test Score (Spatial Planning)
Time frame: Baseline and Week 6
Change in performance on the Spatial Planning timed task, measuring executive function and ability to reorganize numbers into correct order, assessed via the Cognitive Battery Test
6 secondary outcomes
Change in Self-Reported Mental Clarity
Time frame: Baseline, Week 2, Week 4, and Week 6
Change in Self-Reported Focus
Time frame: Baseline, Week 2, Week 4, and Week 6
Change in Self-Reported Memory Function
Time frame: Baseline, Week 2, Week 4, and Week 6
Change in Self-Reported Alertness
Time frame: Baseline, Week 2, Week 4, and Week 6
Change in Self-Reported Mood
Time frame: Baseline, Week 2, Week 4, and Week 6
Change in Self-Reported Brain Fog
Time frame: Baseline, Week 2, Week 4, and Week 6
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 3 Aug 2026.
Related trials for Cognitive Impairment
Recruiting
Early Motor-Cognitive Integrative Training on Cognitive and Motor Performance in Patients With Aneurysmal Subarachnoid Hemorrhage
Subarachnoid Aneurysm Hemorrhage
Recruiting
HEARS-NPS: Addressing Hearing Loss as a Common Unmet Contributor of Neuropsychiatric Symptoms
Alzheimer Disease, Dementia
RecruitingObservational study
Locus Coeruleus and CCHS (Congenital Central Hypoventilation Syndrome)
Ondine Syndrome (Congenital Central Hypoventilation Syndrome)
RecruitingPhase 1
PET Imaging of Phosphodiesterase-4 (PDE4) in Volunteers With Alzheimer Disease (AD) or Mild Cognitive Impairment (MCI)
Alzheimer s Disease, Mild Cognitive Impairment
RecruitingObservational study
Community-based Screening for Alzheimer's Disease
Alzheimer's Disease(AD), Mild Cognitive Impairment (MCI)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Xula Herbs Mind Food Supplement in people with Cognitive Impairment and Brain Fog, run by Xula Wellness LLC at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 9 inclusion and 11 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 3 Aug 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Change in Cognitive Battery Test Score (Polygons) (time frame: Baseline and Week 6). The study lists 6 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 3 Aug 2026.